Literature DB >> 18698279

Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.

Kristen B Levine1, Rachel E Williams, Katherine E Hartmann.   

Abstract

OBJECTIVE: The relationship between vulvovaginal atrophy and female sexual dysfunction is unclear. We investigated this association among sexually active postmenopausal women.
DESIGN: The Menopause Epidemiology Study is a cross-sectional, population-based study of women 40 to 65 years old in the United States chosen from a source population selected by random digit dialing and probability sampling. We focused on sexually active postmenopausal women (N = 1,480) for our analyses. Vulvovaginal atrophy was defined as one or more of the following: vaginal dryness, itching, irritation; pain on urination; or pain or bleeding on intercourse. The Arizona Sexual Experience Survey was used to define female sexual dysfunction. Sexual dysfunction subtypes for desire, arousal, and orgasm difficulties were individually scored. We evaluated demographic, behavioral, reproductive history, and medication covariates for effect modification and confounding. Multivariate logistic regression was used to assess the relationship between vulvovaginal atrophy and female sexual dysfunction.
RESULTS: The prevalence of vulvovaginal atrophy (57%) and female sexual dysfunction (55%) was high. Women with female sexual dysfunction were 3.84 times more likely to have vulvovaginal atrophy than women without female sexual dysfunction (95% CI: 2.99-4.94). Hot flashes modified the association between vulvovaginal atrophy and desire difficulty. Educational level modified the association between vulvovaginal atrophy and arousal difficulty. Parity modified the association between vulvovaginal atrophy and orgasm difficulty.
CONCLUSIONS: This large population-based study provides evidence of an association between vulvovaginal atrophy and overall female sexual dysfunction and its subtypes. Therapies aiming to reduce symptoms of one condition may also relieve symptoms of the other.

Entities:  

Mesh:

Year:  2008        PMID: 18698279     DOI: 10.1097/gme.0b013e31815a5168

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  43 in total

1.  Sexual Function among Women in Midlife: Findings from the Nurses' Health Study II.

Authors:  Christiana von Hippel; Avanti Adhia; Shoshana Rosenberg; S Bryn Austin; Ann Partridge; Rulla Tamimi
Journal:  Womens Health Issues       Date:  2019-05-23

2.  Baseline characteristics and concerns of female cancer patients/survivors seeking treatment at a Female Sexual Medicine Program.

Authors:  Jeanne Carter; Cara Stabile; Barbara Seidel; Raymond E Baser; Abigail R Gunn; Stephanie Chi; Rebecca F Steed; Shari Goldfarb; Deborah J Goldfrank
Journal:  Support Care Cancer       Date:  2015-01-08       Impact factor: 3.603

Review 3.  Assessment of vaginal atrophy: a review.

Authors:  M A Weber; J Limpens; J P W R Roovers
Journal:  Int Urogynecol J       Date:  2014-07-22       Impact factor: 2.894

Review 4.  A biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review.

Authors:  Holly N Thomas; Rebecca C Thurston
Journal:  Maturitas       Date:  2016-02-21       Impact factor: 4.342

5.  Pelvic floor dysfunction in female Sjögren's syndrome: an 8-year audit.

Authors:  Aaron K Budden; Nèvine I D Te West; Allan D Sturgess; Kate H Moore
Journal:  Int Urogynecol J       Date:  2016-03-10       Impact factor: 2.894

6.  The relationship between age and pelvic organ prolapse bother.

Authors:  Casey L Kinman; Courtney A Lemieux; Anubhav Agrawal; Jeremy T Gaskins; Kate V Meriwether; Sean L Francis
Journal:  Int Urogynecol J       Date:  2016-10-20       Impact factor: 2.894

7.  Dyspareunia is associated with decreased frequency of intercourse in the menopausal transition.

Authors:  Holly M Thomas; Cindy L Bryce; Roberta B Ness; Rachel Hess
Journal:  Menopause       Date:  2011-02       Impact factor: 2.953

8.  Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors.

Authors:  Jeanne Carter; Cara Stabile; Barbara Seidel; Raymond E Baser; Shari Goldfarb; Deborah J Goldfrank
Journal:  J Cancer Surviv       Date:  2016-11-21       Impact factor: 4.442

9.  Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.

Authors:  Margery Gass; Joseph Larson; Barbara Cochrane; JoAnn E Manson; Dorothy Lane; Vanessa Barnabei; Judith Ockene; Marcia L Stefanick; Charles Mouton
Journal:  Menopause       Date:  2018-03       Impact factor: 2.953

10.  What Is Genitourinary Syndrome of Menopause and Why Should We Care?

Authors:  Kelly Jo Peters
Journal:  Perm J       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.